肝門部膽管癌的治療現狀與展望_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

李富宇 ,  程南生

四川大學華西醫院膽道外科（成都 610041）;

Corresponding?author：

程南生, Email: nscheng2002@163.com

Keywords：

DOI：

10.7507/1007-9424.201807002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李富宇, 程南生. 肝門部膽管癌的治療現狀與展望. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2018, 25(7): 769-774. doi: 10.7507/1007-9424.201807002 Copy

1.	Dumitrascu T, Chirita D, Ionescu M, et al. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg, 2013, 17(5): 913-924.
2.	Young AL, Igami T, Senda Y, Adair R, et al. Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxford), 2011, 13(7): 483-493.
3.	Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg, 2001, 234(4): 507-519.
4.	董家鴻, 項燦宏. 肝門部膽管癌的精準外科手術治療. 中華消化外科雜志, 2013, 12(3): 170-173.
5.	Saxena A, Chua TC, Chu FC, et al. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg, 2011, 202(3): 310-320.
6.	中華醫學會外科學分會膽道外科學組, 解放軍全軍肝膽外科專業委員會. 肝門部膽管癌診斷和治療指南(2013版). 中華外科雜志, 2013, 51(10): 865-871.
7.	Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg, 2014, 399(6): 693-705.
8.	Liu CL, Fan ST, Lo CM, et al. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg, 2006, 93(12): 1488-1494.
9.	Witzigmann H, Berr F, Ringel U, Caca K, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg, 2006, 244(2): 230-239.
10.	Golfieri R, Giampalma E, Renzulli M, et al. Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo, 2006, 20(6A): 757-760.
11.	Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol, 2005, 14(2): 59-74.
12.	Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg, 2007, 31(6): 1256-1263.
13.	Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg, 2008, 248(2): 273-279.
14.	Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center’s experience. Am J Surg, 2008, 196(2): 160-169.
15.	Robles R, Figueras J, Turrión VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg, 2004, 239(2): 265-271.
16.	Ramacciato G, Nigri G, Bellagamba R, et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg, 2010, 76(11): 1260-1268.
17.	Hemming AW, Mekeel K, Khanna A, et al. Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg, 2011, 212(4): 604-616.
18.	Wang JK, Hu HJ, Shrestha A, et al. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget, 2017, 8(28): 45335-45344.
19.	Hu HJ, Mao H, Tan YQ, et al. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus, 2016, 5: 551.
20.	Hu HJ, Shrestha A, Mao H, et al. Impact of different tumor size cut-off points on survival outcome after curative resection of hilar cholangiocarcinoma. Int J Clin Exp Med, 2016, 9: 6178-6189.
21.	Hu HJ, Zhou RX, Shrestha A, et al. Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma. Oncotarget, 2017, 8(62): 105011-105019.
22.	Dinant S, Gerhards MF, Rauws EA, et al. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol, 2006, 13(6): 872-880.
23.	Tsuchikawa T, Hirano S, Okamura K, et al. Advances in the surgical treatment of hilar cholangiocarcinoma. Expert Rev Gastroenterol Hepatol, 2015, 9(3): 369-374.
24.	魯正, 王冬冬. Bismuth-Corlette Ⅲ、Ⅳ型肝門部膽管癌的手術治療方式. 中華外科雜志, 2016, 54(7): 488-491.
25.	Conci S, Ruzzenente A, Sandri M, et al. What is the most accurate lymph node staging method for perihilar cholangiocarcinoma? Comparison of UICC/AJCC pN stage, number of metastatic lymph nodes, lymph node ratio, and log odds of metastatic lymph nodes. Eur J Surg Oncol, 2017, 43(4): 743-750.
26.	Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392.
27.	Bagante F, Tran T, Spolverato G, et al. Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme. J Am Coll Surg, 2016, 222(5): 750-759.e2.
28.	Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. New York: Springer, 2017.
29.	National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hepatobiliary Cancers, V.1.2018. Available at http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
30.	Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3^rd English edition. J Hepato Biliary Pancreat Sci, 2015, 22(3): 181-196.
31.	Murakami Y, Uemura K, Sudo T, et al. Is para-aortic lymph node metastasis a contraindication for radical resection in biliary carcinoma? World J Surg, 2011, 35(5): 1085-1093.
32.	Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol, 2016, 22(8): 2601-2610.
33.	張輝, 王孟龍. 肝門部膽管癌的可切除性評估. 中華肝膽外科雜志, 2015, 21(11): 789-792.
34.	Zaydfudim VM, Rosen CB, Nagorney DM. Hilar cholangiocarcinoma. Surg Oncol Clin N Am, 2014, 23(2): 247-263.
35.	Ito F, Cho CS, Rikkers LF, et al. Hilar cholangiocarcinoma: current management. Ann Surg, 2009, 250(2): 210-218.
36.	Kow AW, Wook CD, Song SC, et al. Role of caudate lobectomy in type ⅢA and ⅢB hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg, 2012, 36(5): 1112-1121.
37.	Cheng QB, Yi B, Wang JH, et al. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type Ⅲ and Ⅳ. Eur J Surg Oncol, 2012, 38(12): 1197-1203.
38.	Chen W, Ke K, Chen YL. Combined portal vein resection in the treatment of hilar cholangiocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol, 2014, 40(5): 489-495.
39.	Miyazaki M, Kato A, Ito H, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery, 2007, 141(5): 581-588.
40.	Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg, 2010, 252(1): 115-123.
41.	Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg, 2003, 238(5): 720-727.
42.	Wu XS, Dong P, Gu J, et al. Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies. J Gastrointest Surg, 2013, 17(6): 1107-1115.
43.	倪其泓, 王堅. 肝門部膽管癌診斷和治療指南(2013版)的解讀與思考. 肝膽胰外科雜志, 2015, 27(6): 450-454.
44.	Govil S, Reddy MS, Rela M. Surgical resection techniques for locally advanced hilar cholangiocarcinoma. Langenbecks Arch Surg, 2014, 399(6): 707-716.
45.	Schimizzi GV, Jin LX, Davidson JT 4th, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford), 2018, 20(4): 332-339.
46.	Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford), 2013, 15(7): 492-503.
47.	Yu W, Gu Z, Shi S et al. Yu W, Gu Z, Shi S, et al. Effect evaluation of vascular resection for patients with hilar cholangiocarcinoma: original data and meta-analysis. Cell Biochem Biophys, 2014, 69(3): 509-516.
48.	Peng C, Li C, Wen T, et al. Left hepatectomy combined with hepatic artery resection for hilar cholangiocarcinoma: A retrospective cohort study. Int J Surg, 2016, 32: 167-173.
49.	Hu HJ, Jin YW, Zhou RX, et al. Hepatic artery resection for Bismuth type Ⅲ and Ⅳ hilar cholangiocarcinoma: is reconstruction always required?. J Gastrointest Surg, 2018, Mar 6. doi: 10.1007/s11605-018-3711-3.
50.	Alessiani M, Tzakis A, Todo S, et al. Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg, 1995, 180(1): 1-9.
51.	李文杰, 梁雨榮. 肝門部膽管癌的診療現狀. 中華肝膽外科雜志, 2015, 21(4): 281-283.
52.	Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc, 2009, 41(10): 4023-4035.
53.	Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg, 2005, 242(3): 451-461.
54.	Gores GJ. Liver transplantation for cholangiocarcinoma. Liver Transpl, 2015, 21 Suppl 1: S32-S33.
55.	Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation, 2006, 82(12): 1703-1707.
56.	Soares KC, Kamel I, Cosgrove DP, et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr, 2014, 3(1): 18-34.
57.	Valero V 3rd, Cosgrove D, Herman JM, et al. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol, 2012, 6(4): 481-495.
58.	Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer, 2010, 103(4): 469-474.
59.	Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010, 362(14): 1273-1281.
60.	Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg, 2009, 13(8): 1470-1479.
61.	Bridgewater JA, Stubbs C, Primrose JN. BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. J Clin Oncol, 2011, 29(15): 2696.
62.	Glazer ES, Liu P, Abdalla EK, et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg, 2012, 16(9): 1666-1671.
63.	Howell M, Valle JW. The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. Best Pract Res Clin Gastroenterol, 2015, 29(2): 333-343.
64.	蕭嘉銘, 董高宏. 肝門部膽管癌的治療現狀. 中國腫瘤外科雜志, 2015, 7(6): 390-393.
65.	閆炫炫, 李多富, 李汛. 光動力療法在不可切除肝門部膽管癌中的應用. 中國普外基礎與臨床雜志, 2018, 25(4): 488-492.
66.	Ortner ME, Caca K, Berr F,et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology, 2003, 125(5): 1355-163.
67.	Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11): 2426-2430.
68.	Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase Ⅱ pilot study. Cancer, 2003, 97(11): 2783-2790.

1. Dumitrascu T, Chirita D, Ionescu M, et al. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg, 2013, 17(5): 913-924.
2. Young AL, Igami T, Senda Y, Adair R, et al. Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB (Oxford), 2011, 13(7): 483-493.
3. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg, 2001, 234(4): 507-519.
4. 董家鴻, 項燦宏. 肝門部膽管癌的精準外科手術治療. 中華消化外科雜志, 2013, 12(3): 170-173.
5. Saxena A, Chua TC, Chu FC, et al. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg, 2011, 202(3): 310-320.
6. 中華醫學會外科學分會膽道外科學組, 解放軍全軍肝膽外科專業委員會. 肝門部膽管癌診斷和治療指南(2013版). 中華外科雜志, 2013, 51(10): 865-871.
7. Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg, 2014, 399(6): 693-705.
8. Liu CL, Fan ST, Lo CM, et al. Improved operative and survival outcomes of surgical treatment for hilar cholangiocarcinoma. Br J Surg, 2006, 93(12): 1488-1494.
9. Witzigmann H, Berr F, Ringel U, Caca K, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg, 2006, 244(2): 230-239.
10. Golfieri R, Giampalma E, Renzulli M, et al. Unresectable hilar cholangiocarcinoma: multimodality approach with percutaneous treatment associated with radiotherapy and chemotherapy. In Vivo, 2006, 20(6A): 757-760.
11. Singhal D, van Gulik TM, Gouma DJ. Palliative management of hilar cholangiocarcinoma. Surg Oncol, 2005, 14(2): 59-74.
12. Hasegawa S, Ikai I, Fujii H, et al. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg, 2007, 31(6): 1256-1263.
13. Ito F, Agni R, Rettammel RJ, et al. Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg, 2008, 248(2): 273-279.
14. Konstadoulakis MM, Roayaie S, Gomatos IP, et al. Aggressive surgical resection for hilar cholangiocarcinoma: is it justified? Audit of a single center’s experience. Am J Surg, 2008, 196(2): 160-169.
15. Robles R, Figueras J, Turrión VS, et al. Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma. Ann Surg, 2004, 239(2): 265-271.
16. Ramacciato G, Nigri G, Bellagamba R, et al. Univariate and multivariate analysis of prognostic factors in the surgical treatment of hilar cholangiocarcinoma. Am Surg, 2010, 76(11): 1260-1268.
17. Hemming AW, Mekeel K, Khanna A, et al. Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg, 2011, 212(4): 604-616.
18. Wang JK, Hu HJ, Shrestha A, et al. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma? Oncotarget, 2017, 8(28): 45335-45344.
19. Hu HJ, Mao H, Tan YQ, et al. Clinical value of preoperative serum CA 19-9 and CA 125 levels in predicting the resectability of hilar cholangiocarcinoma. Springerplus, 2016, 5: 551.
20. Hu HJ, Shrestha A, Mao H, et al. Impact of different tumor size cut-off points on survival outcome after curative resection of hilar cholangiocarcinoma. Int J Clin Exp Med, 2016, 9: 6178-6189.
21. Hu HJ, Zhou RX, Shrestha A, et al. Relationship of tumor size with pathological and prognostic factors for hilar cholangiocarcinoma. Oncotarget, 2017, 8(62): 105011-105019.
22. Dinant S, Gerhards MF, Rauws EA, et al. Improved outcome of resection of hilar cholangiocarcinoma (Klatskin tumor). Ann Surg Oncol, 2006, 13(6): 872-880.
23. Tsuchikawa T, Hirano S, Okamura K, et al. Advances in the surgical treatment of hilar cholangiocarcinoma. Expert Rev Gastroenterol Hepatol, 2015, 9(3): 369-374.
24. 魯正, 王冬冬. Bismuth-Corlette Ⅲ、Ⅳ型肝門部膽管癌的手術治療方式. 中華外科雜志, 2016, 54(7): 488-491.
25. Conci S, Ruzzenente A, Sandri M, et al. What is the most accurate lymph node staging method for perihilar cholangiocarcinoma? Comparison of UICC/AJCC pN stage, number of metastatic lymph nodes, lymph node ratio, and log odds of metastatic lymph nodes. Eur J Surg Oncol, 2017, 43(4): 743-750.
26. Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection. Ann Surg, 2001, 233(3): 385-392.
27. Bagante F, Tran T, Spolverato G, et al. Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme. J Am Coll Surg, 2016, 222(5): 750-759.e2.
28. Amin MB, Edge S, Greene F, et al. American Joint Committee on Cancer (AJCC) Cancer Staging Manual. 8th ed. New York: Springer, 2017.
29. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hepatobiliary Cancers, V.1.2018. Available at http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
30. Miyazaki M, Ohtsuka M, Miyakawa S, et al. Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3^rd English edition. J Hepato Biliary Pancreat Sci, 2015, 22(3): 181-196.
31. Murakami Y, Uemura K, Sudo T, et al. Is para-aortic lymph node metastasis a contraindication for radical resection in biliary carcinoma? World J Surg, 2011, 35(5): 1085-1093.
32. Hu HJ, Mao H, Shrestha A, et al. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol, 2016, 22(8): 2601-2610.
33. 張輝, 王孟龍. 肝門部膽管癌的可切除性評估. 中華肝膽外科雜志, 2015, 21(11): 789-792.
34. Zaydfudim VM, Rosen CB, Nagorney DM. Hilar cholangiocarcinoma. Surg Oncol Clin N Am, 2014, 23(2): 247-263.
35. Ito F, Cho CS, Rikkers LF, et al. Hilar cholangiocarcinoma: current management. Ann Surg, 2009, 250(2): 210-218.
36. Kow AW, Wook CD, Song SC, et al. Role of caudate lobectomy in type ⅢA and ⅢB hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg, 2012, 36(5): 1112-1121.
37. Cheng QB, Yi B, Wang JH, et al. Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type Ⅲ and Ⅳ. Eur J Surg Oncol, 2012, 38(12): 1197-1203.
38. Chen W, Ke K, Chen YL. Combined portal vein resection in the treatment of hilar cholangiocarcinoma: a systematic review and meta-analysis. Eur J Surg Oncol, 2014, 40(5): 489-495.
39. Miyazaki M, Kato A, Ito H, et al. Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery, 2007, 141(5): 581-588.
40. Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg, 2010, 252(1): 115-123.
41. Ebata T, Nagino M, Kamiya J, et al. Hepatectomy with portal vein resection for hilar cholangiocarcinoma: audit of 52 consecutive cases. Ann Surg, 2003, 238(5): 720-727.
42. Wu XS, Dong P, Gu J, et al. Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies. J Gastrointest Surg, 2013, 17(6): 1107-1115.
43. 倪其泓, 王堅. 肝門部膽管癌診斷和治療指南(2013版)的解讀與思考. 肝膽胰外科雜志, 2015, 27(6): 450-454.
44. Govil S, Reddy MS, Rela M. Surgical resection techniques for locally advanced hilar cholangiocarcinoma. Langenbecks Arch Surg, 2014, 399(6): 707-716.
45. Schimizzi GV, Jin LX, Davidson JT 4th, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford), 2018, 20(4): 332-339.
46. Abbas S, Sandroussi C. Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB (Oxford), 2013, 15(7): 492-503.
47. Yu W, Gu Z, Shi S et al. Yu W, Gu Z, Shi S, et al. Effect evaluation of vascular resection for patients with hilar cholangiocarcinoma: original data and meta-analysis. Cell Biochem Biophys, 2014, 69(3): 509-516.
48. Peng C, Li C, Wen T, et al. Left hepatectomy combined with hepatic artery resection for hilar cholangiocarcinoma: A retrospective cohort study. Int J Surg, 2016, 32: 167-173.
49. Hu HJ, Jin YW, Zhou RX, et al. Hepatic artery resection for Bismuth type Ⅲ and Ⅳ hilar cholangiocarcinoma: is reconstruction always required?. J Gastrointest Surg, 2018, Mar 6. doi: 10.1007/s11605-018-3711-3.
50. Alessiani M, Tzakis A, Todo S, et al. Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg, 1995, 180(1): 1-9.
51. 李文杰, 梁雨榮. 肝門部膽管癌的診療現狀. 中華肝膽外科雜志, 2015, 21(4): 281-283.
52. Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc, 2009, 41(10): 4023-4035.
53. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg, 2005, 242(3): 451-461.
54. Gores GJ. Liver transplantation for cholangiocarcinoma. Liver Transpl, 2015, 21 Suppl 1: S32-S33.
55. Heimbach JK, Gores GJ, Haddock MG, et al. Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma. Transplantation, 2006, 82(12): 1703-1707.
56. Soares KC, Kamel I, Cosgrove DP, et al. Hilar cholangiocarcinoma: diagnosis, treatment options, and management. Hepatobiliary Surg Nutr, 2014, 3(1): 18-34.
57. Valero V 3rd, Cosgrove D, Herman JM, et al. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol, 2012, 6(4): 481-495.
58. Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer, 2010, 103(4): 469-474.
59. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med, 2010, 362(14): 1273-1281.
60. Murakami Y, Uemura K, Sudo T, et al. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg, 2009, 13(8): 1470-1479.
61. Bridgewater JA, Stubbs C, Primrose JN. BILCAP: A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. J Clin Oncol, 2011, 29(15): 2696.
62. Glazer ES, Liu P, Abdalla EK, et al. Neither neoadjuvant nor adjuvant therapy increases survival after biliary tract cancer resection with wide negative margins. J Gastrointest Surg, 2012, 16(9): 1666-1671.
63. Howell M, Valle JW. The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. Best Pract Res Clin Gastroenterol, 2015, 29(2): 333-343.
64. 蕭嘉銘, 董高宏. 肝門部膽管癌的治療現狀. 中國腫瘤外科雜志, 2015, 7(6): 390-393.
65. 閆炫炫, 李多富, 李汛. 光動力療法在不可切除肝門部膽管癌中的應用. 中國普外基礎與臨床雜志, 2018, 25(4): 488-492.
66. Ortner ME, Caca K, Berr F,et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology, 2003, 125(5): 1355-163.
67. Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol, 2005, 100(11): 2426-2430.
68. Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase Ⅱ pilot study. Cancer, 2003, 97(11): 2783-2790.

Previous Article
頸內靜脈大隱靜脈轉流術在上腔靜脈破裂中的應用一例
Next Article
肝門部膽管癌根治術區域淋巴結清掃范圍探討

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

肝門部膽管癌的治療現狀與展望

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content